IWMF, volunteers from the IWMF Affiliates, and WM researchers develop publications including Booklets, Treatment Guides, and Facts Sheets to provide the newly diagnosed and veteran patients, as well as their caregivers, with up-to-date information about Waldenstrom’s macroglobulinemia and how to treat it.
The IWMF does not warranty the content of these publications. We are making these available to you as information, and we encourage you to discuss what may be appropriate to you with your hematologist/oncologist.
All languages
By Guy Sherwood, M.D., 2014
Revised Linda Nelson, 2018
A comprehensive review of immunology and genetics as it relates to WM.
Written & compiled by Debra Entin, Glenn Cantor, Linda Nelson, Tom Hoffmann, & Sue Herms, 2022.
This booklet is designed to help patients with WM understand the basic functions of the bone marrow and how those are affected by our disease, including the bone marrow biopsy procedure and medical tests.
Written by Stephen M. Ansell, M.D., Ph.D, Carl Harrington, Steven Treon, M.D., Ph.D., 2023
Essential Information: A Patient’s Guide on Waldenstrom’s Macroglobulinemia.
By Peter DeNardis, Marcia Klepac, Elena Malunis, and Linda Nelson, 2017.
Revised Linda Nelson, 2019
This booklet answers frequently asked questions about WM in a very readable format for those who may not have a strong background in biology.
Written & compiled by Guy Sherwood, M.D., Bret Blakeslee, Sue Herms, & Peter DeNardis, 2015.
Revised Linda Nelson, Glenn Cantor, & Sue Herms, 2023.
This glossary is designed to help patients with WM learn and understand pertinent medical terms that relate to the disease.
By Guy Sherwood, M.D., 2007
Revised by Linda Nelson and Sue Herms, 2016, 2020
A reference booklet of medical terms and tests, this revision places particular emphasis on expanding the explanation of the Complete Blood Count and on Immunoglobulins. Tests for beta-2 microglobulin and light chains have been added, as has genetics testing.
By Guy Sherwood and Sue Herms, Revised 2010, 2014.
Revised Sue Herms and Linda Nelson, 2017.
Revised Glenn Cantor, Sue Herms, and Linda Nelson 2022.
Designed to provide detailed answers to questions about Waldenstrom’s macroglobulinemia, including a full glossary of terms.
By Dipti Talaulikar, M.D., Constantine Tam, M.D., et al, 2022
This booklet is a consensus established by the Australian Medical Scientific Advisory Group, which consists of a panel of haematologists across Australia, and it is provided by the IWMF Affiliate (WMozzies) in Australia.
By Christian Buske, M.D., and George Hess, M.D., 2014
Revised 2019
This booklet is provided by the IWMF-Affiliate Morbus Waldenstrom (MOWA) in Germany.
By Shirley D’Sa, M.D., 2014, updated 2018, updated 2020.
This booklet is provided by the IWMF Affiliate Waldenstrom’s UK (WMUK). The drugs mentioned in the booklet are noted by their generic names and by their UK-specific trade names and may/may not be available in UK/US (or elsewhere) unless in the context of a clinical trial.
All languages
These Treatment Options Guides review drug therapies and treatment guidelines currently used in the management of Waldenstrom’s macroglobulinemia. They are designed to provide patients with some of the necessary information to allow them to participate with their physicians in determining the best course of treatment for their disease.
By Suzanne Herms, 2016
Revised 2021
This Guide discusses alkylating agents, such as chlorambucil (Leukeran), cyclophosphamide (Cytoxan), melphalan (Alkeran) and bendamustine (Bendeka, Treanda, Levact), as well as nucleoside analogs, such as fludarabine (Fludara) and cladribine (2CdA or Leustatin).
By Suzanne Herms, 2016
Revised 2021
This Guide discusses monoclonal antibodies, such as rituximab (Rituxan or Mabthera), ofatumumab (Arzerra), and alemtuzumab (Campath).
By Suzanne Herms, 2016
Revised 2021
This Guide includes proteasome inhibitors, such as bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro).
By Suzanne Herms, 2016
Revised 2021
This Guide discusses targeted therapies/pathway inhibitors to B-cell signaling, such as ibrutinib (Imbruvica) and everolimus (RAD001 or Afinitor).
All languages
These are short summaries that include information about WM, common treatments, and other associated topics.